Drug intelligence / Profile preview

melatonin + memantine

Development stage: Unknown
Lead developer: Pathos AI
Modality: Small Molecules
Administration: Sublingual

Overview

Miladean is a fixed-dose combination of melatonin and memantine developed by Valenta Pharmaceuticals. It is designed to address cognitive and behavioral impairments by combining the neuroprotective and NMDA receptor-antagonizing properties of memantine with the sleep-regulating and antioxidant effects of melatonin. The drug is typically administered sublingually. Clinical studies have explored its efficacy in children and adolescents with hyperkinetic conduct disorder, schizotypal disorder, and schizophrenia, showing improvements in attention, hyperactivity-impulsivity, and sleep quality. It is approved in certain regions for CNS disorders and dementia risk factors.

Brand names: Miladean

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on melatonin + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on melatonin + memantine.

Explore the full profile